Virtual Event

2020年10月06日 (火) 午前 10:00 - 2020年10月07日 (水) 午後 5:25

(US Eastern Standard Time)

Fort Washington, PA 19034

Biosimilars Conference

Session 9: Regulatory Landscape – Ask the Regulators and Closing Remarks

Session Chair(s)

Sarah  Yim, MD

Sarah Yim, MD

Director, Office of Therapeutic Biologics and Biosimilars, OND, CDER

FDA, United States

This session focuses on the regulator’s perspective and provides an opportunity for interactive Q&A. The session will begin with brief presentations of the highlights of recent regulatory developments from the mentioned regulators, followed by a panel question and answer session.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Describe recent biosimilar-related regulatory developments in the participating speakers’ countries
  • Better interpret the regulatory perspective on biosimilar-related development in the participating countries
  • Better answer biosimilar-related development questions from a regulatory perspective

Speaker(s)

Hillel P Cohen, PhD

Closing Remarks

Hillel P Cohen, PhD

Retired, United States

Biosimilars Expert

Jian  Wang, MD, PhD

Speaker

Jian Wang, MD, PhD

Health Canada, Canada

Division Manager, Clinical Review Division – Heamatology/Oncology

Andrea  Laslop, MD

Speaker

Andrea Laslop, MD

Austrian Medicines and Medical Devices Agency, Austria

Head of Scientific Office

Eva  Temkin, JD

Speaker

Eva Temkin, JD

King & Spalding LLP, United States

Partner, FDA and Life Sciences

Stacey  Ricci

Speaker

Stacey Ricci

US FDA, United States

Director, Scientific Review Staff, OTBB, CDER

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。